Trevi Therapeutics (TRVI) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Trevi ended Q1 2026 with approximately $172 million in cash, cash equivalents, and marketable securities.

Recent Offering: The company completed a $162 million underwritten common stock offering in April 2026, which was well-received and extended the cash runway into 2030.

Funding Plans: The cash resources will support ongoing clinical trials, including those for IPF-related chronic cough and refractory chronic cough (RCC).

2Strategic Updates and Business Highlights

FDA Alignment: Following a positive meeting with the FDA, Trevi has finalized protocols for Phase III trials related to IPF-related chronic cough and plans to initiate the first study this quarter.

Non-IPF-ILD Program: The company intends to submit a protocol for a Phase II/III study for non-IPF interstitial lung disease-related chronic cough, with initiation expected in the second half of 2026.

Refractory Chronic Cough Trials: A Phase IIb dose-ranging trial for RCC is set to begin this quarter, with a sample size reestimation (SSRE) expected by Q4 2026.

Intellectual Property: Trevi secured a core method of treatment patent for IPF-related chronic cough in Europe, extending protection through 2039, with additional applications aimed at extending coverage to 2046.

3Forward Guidance and Outlook

Clinical Trial Timeline: Trevi anticipates initiating two pivotal studies for chronic cough this year and expects to report top-line data from the Phase IIb RCC trial in 2027.

Investor Engagement: The company is hosting an Investor and Analyst Day to provide detailed timelines and insights into upcoming clinical trials and market research.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: The upcoming readout of a competitor's P2X3 antagonist could impact Trevi's market positioning in RCC. If results are strong, it may affect enrollment and competitive dynamics.

Placebo Response: There are concerns regarding potential high placebo responses in RCC trials, which could complicate data interpretation and trial outcomes.

Resource Allocation: Managing multiple clinical programs with a small team poses challenges, though management expressed confidence in their capabilities and recent hiring efforts to scale operations.

5Notable Q&A Insights

FDA Meeting Goals: The upcoming FDA meeting aims to discuss the Phase IIb/III protocol for non-IPF-ILD chronic cough, focusing on patient population and dose selection strategies.

Competitive Positioning: Management believes that even if competitors succeed, Trevi's differentiated mechanism of action and existing data will support its position in the market.

Dyspnea as a Metric: Dyspnea is a significant quality of life metric for patients, and its modulation could enhance the value proposition of Trevi's therapies.

Enrollment Strategy: Trevi plans to include patients with prior P2X3 antagonist experience in the RCC trial, provided they meet eligibility criteria, reflecting a broader approach to patient selection. Overall, Trevi Therapeutics is positioned for significant clinical advancements in 2026, with a strong cash position and strategic initiatives aimed at addressing chronic cough in various patient populations, despite facing competitive and operational challenges.